NICE recommends Entyvio (vedolizumab) from Takeda to treat ulcerative colitis
The National Institute for Health and Care Excellence (NICE) has issued guidelines recommending that Entyvio (vedolizumab) from Takeda, should be considered for adults with moderate-to-severe ulcerative colitis when conventional therapy or TNF-alpha inhibitors are ineffective or cannot be tolerated. People should be able to have the treatment until it stops working or surgery is needed. Their condition should be assessed 12 months after they start taking vedolizumab. If they still have symptoms but it is clear that the treatment is helping, they can continue to have it. If they no longer have symptoms, treatment could be stopped, and later restarted if symptoms return. The NICE endorsement is dependent on a confidential patient access scheme offering the drug at a reduced rate to help secure its cost effectiveness.
Related news and insights
Amicus Therapeutics announced that the European Medicines Agency validated the Marketing Authorization Applications (MAA) for AT GAA (cipaglucosidase alfa + miglustat), the Company’s investigational two-component therapy for the treatment of Pompe disease.
Bristol Myers Squibb announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
BeiGene, Ltd. and EUSA Pharma (UK), Ltd. announced that the China National Medical Products Administration (NMPA) has approved Sylvant (siltuximab for injection) for the treatment of adult patients with multicentric Castleman disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpes virus-8 (HHV-8) negative, also known as idiopathic MCD (iMCD).